

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

12 Jun 2026

### Evaluation of antioxidant effects of NAC and vitamin B6 in comparison with NAC and placebo, in chemical warfare victims Chronic pulmonary lesions

#### Protocol summary

##### Study aim

Evaluation of antioxidant effects of NAC and vitamin B6 in comparison with NAC alone, in chemical warfare victims Chronic pulmonary lesions

##### Design

This study is a randomized, double-blinded, placebo-controlled, parallel, clinical trial, in which 56 War chemical gas victims with chronic lung lesions, who will consciously and freely satisfy to participate in the study, will be entered the trial and accidentally will be assigned to intervention or control group, then be monitored for 6 weeks.

##### Settings and conduct

Patients will randomly assigned to intervention or control group and, according to their group's protocol, will take the medication for 6 weeks. Prior to the intervention, patients' demographic information and chemical warfare gas history, quality of life, and levels of oxidative stress biomarkers will recorded. Six weeks later, at the end of the study, the following will be reviewed.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Chronic lung lesions caused by war chemical gases have been proven; According to the patient's spirometry results, the pulmonary injury is not severe; The patient should have freely informed written consent to participate in the study. Exclusion criteria: Suffering from lung function-related diseases of lung origin, including asthma, bronchiectasis, etc. Suffering from lung function-related diseases of non-lung origin, including ALS, kyphosis, etc.

##### Intervention groups

In intervention group, patients will receive 600 mg of NAC effervescent tablets, 3 times a day, and Tablet vitamin B6 50 mg once daily for 6 weeks. In control group, patients will receive 600 mg of NAC effervescent tablets, 3 times a day, and Tablet vitamin B6 placebo once daily for 6 weeks.

#### Main outcome variables

Spirometry parameters changes

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20080901001165N54**

Registration date: **2020-05-23, 1399/03/03**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-05-23, 1399/03/03**

Update count: **0**

##### Registration date

2020-05-23, 1399/03/03

##### Registrant information

##### Name

Yunes Panahi

##### Name of organization / entity

Baqiyatallah University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8821 1524

##### Email address

yunespanahi@bmsu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-11-11, 1398/08/20

##### Expected recruitment end date

2020-11-10, 1399/08/20

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of antioxidant effects of NAC and vitamin B6 in comparison with NAC and placebo, in chemical warfare victims Chronic pulmonary lesions

**Public title**

Evaluation of antioxidant effects of NAC and vitamin B6 in comparison with NAC and placebo, in chemical warfare victims Chronic pulmonary lesions

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Chronic lung lesions caused by war chemical gases have been proven; According to the patient's spirometry results, the pulmonary injury is not severe; The patient should have freely informed written consent to participate in the study.

**Exclusion criteria:**

Suffering from lung function-related diseases of lung origin, including asthma, bronchiectasis, etc. Suffering from lung function-related diseases of non-lung origin, including ALS, kyphosis, etc.

**Age**

From **18 years** old

**Gender**

Male

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**

Target sample size: **56**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Block Randomization method is used to randomized the patients. For randomization, we visited the [www.sealedenvelope.com](http://www.sealedenvelope.com), then randomization tab and make a list option were selected, the number of intervention groups, sample size, block size (which was selected due to the small sample size, 4 )were entered the intended locations, then a random list containing the pattern of patient allocation was obtained in two intervention groups.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Both patients and physicians participating in this clinical trial are blinded about the prescribed type of drug (main drug / placebo).

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Baqiyatallah Medical Sciences University

**Street address**

Mullasadra St., Vanak Sq.

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۳۳۵۹۱۵۳۷۱

**Approval date**

2017-11-03, 1396/08/12

**Ethics committee reference number**

IR.BMSU.REC.1396.721

**Health conditions studied****1****Description of health condition studied**

war chemical gas pulmonary disease

**ICD-10 code**

J68.4

**ICD-10 code description**

Chronic respiratory conditions due to chemicals, gases, fumes and vapors

**Primary outcomes****1****Description**

Spirometry parameters changes

**Timepoint**

Before intervention, then 6 weeks later

**Method of measurement**

Spirometer

**Secondary outcomes****1****Description**

Quality of life

**Timepoint**

Before intervention, then 6 weeks later

**Method of measurement**

ACT Questionnaire

**2****Description**

Total antioxidant capacity

**Timepoint**

Before intervention, then 6 weeks later

**Method of measurement**

Total Antioxidant Capacity Assay Kit

**3****Description**

Malondialdehyde (MDA)

**Timepoint**

before intervention, then 6 weeks later

**Method of measurement**

human Elisa kit

**4****Description**

Superoxide dismutase (SOD)

**Timepoint**

before intervention, then 6 weeks later

**Method of measurement**

human Elisa kit

**Intervention groups****1****Description**

Intervention group: NAC effervescent tablets 600 mg, 3 times a day, and 50 mg of vitamin B6 tablets, PO, daily, for 6 weeks.

**Category**

Treatment - Drugs

**2****Description**

Control group: NAC effervescent tablets 600 mg, 3 times a day, and Vitamin B6 Placebo tablets, PO, daily, for 6 weeks.

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Baqiyatallah Hospital

**Full name of responsible person**

Mostafa Ghanei

**Street address**

Mollasadra St., Vanak Sq.

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۳۵۹۱۵۳۷۱

**Phone**

+98 21 8248 2503

**Email**

mghaneister@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Vice Chancellor for Research, Baqiyatallah University of Medical Sciences

**Full name of responsible person**

Gholamhosein Alishiri

**Street address**

Mollasadra St., Vanak Sq.

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۳۵۹۱۵۳۷۱

**Phone**

+98 21 8248 2503

**Email**

R.bmsu@yahoo.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice Chancellor for Research, Baqiyatallah University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Mohammadjavad Ershadi

**Position**

Assistant

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pulmonary disease

**Street address**

Mollasadra St., Vanak Sq.

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۳۵۹۱۵۳۷۱

**Phone**

+98 21 8248 2503

**Email**

mjershad@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Bagheiat-allah University of Medical Sciences

**Full name of responsible person**

Yunes Panahi

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Critical Care Pharmacotherapy

**Street address**

Mollasadra St., Vanak Sq.

**City**

Tehran

**Province**

Tehran

**Postal code**

1435916471

**Phone**

+98 21 8248 2503

**Email**

Yunespanahi@yahoo.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Parisa Kianpour

**Position**

Assistant

**Latest degree**

Specialist

**Other areas of specialty/work**

Pharmacotherapy

**Street address**

Pharmacy faculty, Tehran University of Medical Science, 16-Azar Ave., Enghelab Sq.

**City**

Tehran

**Province**

Tehran

**Postal code**

1991953381

**Phone**

+98 21 6695 4709

**Email**

Parisa\_kianpour@yahoo.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available